Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Sinco Pharmaceutical Holdings OCF Margin %?
Sinco Pharmaceutical HoldingsHKSE:06833 -0.60%44 OCF Margin % is 24.85% as of Dec. 2025, which is 396% above its 10-year median of 5.01. GuruFocus rates HKSE:06833 with a GF Score™ of 44/100 and a GF Value™ of HK$0.19 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 118 Medical Distribution companies, Sinco Pharmaceutical Holdings ranks better than 88.14% on this metric.
The historical rank and industry rank for Sinco Pharmaceutical Holdings's OCF Margin % or its related term are showing as below:
HKSE:06833'
s OCF Margin % Range Over the Past 10 Years
Min: -44.46 Med: 5.01 Max: 26.85
Current: 10.03
During the past 12 years, the highest OCF Margin % of Sinco Pharmaceutical Holdings was 26.85%. The lowest was -44.46%. And the median was 5.01%.
HKSE:06833's OCF Margin % is ranked better than 88.14% of 118
companies
in the Medical Distribution industry
Industry Median: 1.76
vs HKSE:06833: 10.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06833 vs MCK, COR, CAH: OCF Margin % Comparison
For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinco Pharmaceutical Holdings OCF Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Sinco Pharmaceutical Holdings's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinco Pharmaceutical Holdings (HKSE:06833) has a OCF Margin % of 24.85% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sinco Pharmaceutical Holdings and its competitors. This is 396% above median its historical median of 5.01. According to the industry distribution chart, Sinco Pharmaceutical Holdings ranks #14 out of 118 companies in the Medical Distribution industry, placing it in the top 11.9%.
Is Sinco Pharmaceutical Holdings' OCF Margin % too high?
Sinco Pharmaceutical Holdings' current OCF Margin % of 24.85% is 396% above median its 10-year median of 5.01. The Medical Distribution industry median OCF Margin % is 1.76. Sinco Pharmaceutical Holdings' value of 24.85% is 1311.9% above this industry median. Based on the distribution chart, Sinco Pharmaceutical Holdings ranks #14 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinco Pharmaceutical Holdings has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinco Pharmaceutical Holdings' OCF Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinco Pharmaceutical Holdings ranks #14 out of 118 companies for OCF Margin %. This places Sinco Pharmaceutical Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 1.76. Sinco Pharmaceutical Holdings' value of 24.85% is 1311.9% above this benchmark. While the company's 10-year median is 5.01 vs. the industry median of 1.76, Sinco Pharmaceutical Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Distribution company?
The median OCF Margin % among Medical Distribution companies is 1.76, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinco Pharmaceutical Holdings's current OCF Margin % of 24.85% is 1311.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sinco Pharmaceutical Holdings and its competitors. For the Medical Distribution industry, the median OCF Margin % is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinco Pharmaceutical Holdings's current OCF Margin % is 24.85%, which is 396% above median its own 10-year median of 5.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinco Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings (HKSE:06833) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.17 — trading 12.6% below its estimated fair value. The current OCF Margin % is 24.85%, which is 396% above median its 10-year median of 5.01 and 1311.9% above the Medical Distribution industry median of 1.76. Sinco Pharmaceutical Holdings' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Sinco Pharmaceutical Holdings (HKSE:06833), the current OCF Margin % is 24.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinco Pharmaceutical Holdings (HKSE:06833) Overvalued in 2026?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of HK$0.17 is trading 12.6% below its estimated GF Value™ of HK$0.19.
GuruFocus considers Sinco Pharmaceutical Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:06833:
OCF Margin %: 24.85% (396% above median its 10-year median of 5.01)
GF Value™: HK$0.19 vs. price of HK$0.17 (12.6% below fair value)
Industry Position: 1311.9% above the Medical Distribution median (#14 of 118)
No single metric tells the full story. See the HKSE:06833 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.
44GF Score
Get the complete analysis for HKSE:06833
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06833 has been successfully added to your 
